1. Amado, Defne A, Davidson, Beverly L. 2021. Gene therapy for ALS: A review. In Molecular therapy : the journal of the American Society of Gene Therapy, 29, 3345-3358. doi:10.1016/j.ymthe.2021.04.008. https://pubmed.ncbi.nlm.nih.gov/33839324/
2. Costa, Rafael G, Conceição, André, Matos, Carlos A, Nóbrega, Clévio. 2024. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease. In Cell death & disease, 15, 415. doi:10.1038/s41419-024-06812-5. https://pubmed.ncbi.nlm.nih.gov/38877004/
3. Wang, Ming-Dong, Gomes, James, Cashman, Neil R, Little, Julian, Krewski, Daniel. 2014. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS--a systematic review and meta-analysis of observational studies. In PloS one, 9, e105534. doi:10.1371/journal.pone.0105534. https://pubmed.ncbi.nlm.nih.gov/25148523/
4. Elden, Andrew C, Kim, Hyung-Jun, Hart, Michael P, Bonini, Nancy M, Gitler, Aaron D. . Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. In Nature, 466, 1069-75. doi:10.1038/nature09320. https://pubmed.ncbi.nlm.nih.gov/20740007/
5. Scoles, Daniel R, Gandelman, Mandi, Paul, Sharan, Jadhav, Ajit, Pulst, Stefan M. 2022. A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2. In The Journal of biological chemistry, 298, 102228. doi:10.1016/j.jbc.2022.102228. https://pubmed.ncbi.nlm.nih.gov/35787375/
6. Wiggs, Janey L, Pasquale, Louis R. . Genetics of glaucoma. In Human molecular genetics, 26, R21-R27. doi:10.1093/hmg/ddx184. https://pubmed.ncbi.nlm.nih.gov/28505344/
智鼠故事 
